Muscular side effects of statins

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 2, 2002, Pages 163-171

  Sinzinger, Helmut ^a   Wolfram, Roswitha ^a   Peskar, Bernhard A ^a  

^a Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

Author keywords

Creatine phosphokinase; Muscle pains; Myopathy; Oxidation injury; Physical activity; Statins

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BEZAFIBRATE; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; UBIDECARENONE;

CARDIOVASCULAR DISEASE; DRUG EFFECT; ELECTROMYOGRAM; EXERCISE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; MYOPATHY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SYMPTOMATOLOGY; ADULT; BLOOD; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; METABOLISM; MIDDLE AGED; MUSCLE DISEASE; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CREATINE KINASE; FEMALE; HUMAN; MALE; MIDDLE AGE; MUSCULAR DISEASES; RISK FACTORS; HUMANS; MIDDLE AGED;

EID: 0035988137     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200208000-00001     Document Type: Review

References (56)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Group
3. Lowering LDL-cholesterol: Questions from recent meta-analysis and -subreb analysis of clinical trials data: Issues from the Interdisciplinary Council of Reducing the Risk for Coronary Heart Disease
4. The treatment of coronary heart disease. An update. Part 3: Statins beyond cholesterol lowering
5. Lovastatin therapy reduces low-density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications for the pathophysiology of apoB production
6. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl conenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition
7. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
8. Drugs used in the treatment of hyperlipoproteinemias
9. Lipid-lowering drugs and risk of myopathy: A population-based follow-up study
10. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
11. 10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical overview
12. Increased lipid peroxidation in a patient with CK elevation and muscle pain during statin therapy
13. Oxidation injury may also occur in statin-treated patients without enzyme elevation and myopathy
14. Massive rhabdomyolysis and simvastatin
15. Rhabdomyolysis and renal injury with lovastatin use
16. ACE-inhibitor rather than HMG-Co-enzyme-A-reductase inhibitor causative for CK-elevation? - A case report
17. m-sestamibi leg scintigraphy
18. Statin-induced myopathy does not show up in MIBI-scintigraphy
19. Plasma ubiquinol-10 is decreased in patients with hyperlipidemia
20. 10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation
21. Lovastatin decreases coenzyme Q levels in humans
22. Plasma coenzyme Q (ubiquinone) concentration in patients treated with simvastatin
23. Pravastatin-associated myopathy. Report of a case
24. 10 and coronary artery disease
25. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia
26. 10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors
27. 10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study
28. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits
29. The effect of pravastatin and atorvastatin on coenzyme Q10
30. New lipid lowering drugs and new effects of old drugs
31. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
32. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors
33. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors
34. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A reductase inhibitors without CK-elevation?
35. The isoprostanes: Current knowledge and direction of future research
36. 2α in heterozygous hypercholesterolemia
37. Increased lipid peroxidation in patients with rhabdomyolysis
38. 2α is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy
39. 2α in statin-induced myopathy
40. 2-isoprostane excretion rate and diurnal variation in human urine
41. 2α after restarting smoking
42. Increase in circulating products of lipid peroxidation (F2-isoprostanes in smokers). Smoking as a cause of oxidative damage
43. Essential fatty acids as possible mediators of the action of statins
44. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment
45. Flue-like response on statins
46. Lovastatin increases exercise-induced skeletal muscle injury
47. Enhanced myopathy following administration of hypolipidemic agents under methane anesthesia
48. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin and simvastatin, using neonatal rat skeletal myocytes
49. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
50. Rhabdomyolysis secondary to lovastatin therapy
51. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors simvastatin and pravastatin
52. Statin associated myopathy with normal and abnormal creatine kinase: Clinical, pathologic and biochemical features
53. Isolation of a quinone from beef heart mitochondria
54. Vernünftiger umgang mit medikamenten. Blutfette
55. Statine - Einige monate danach